2022
DOI: 10.1111/ijlh.13863
|View full text |Cite|
|
Sign up to set email alerts
|

Plasmablastic lymphoma: An update

Abstract: Plasmablastic lymphoma (PBL) is a highly aggressive B cell non-Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL in the region. Laboratory features in PBL may overlap with plasmablastic myeloma and other large B cell lymphomas with plasmablastic or immunoblastic morphology leading to diagnostic dilemmas. There are, however, p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
12
0
6

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 30 publications
(18 citation statements)
references
References 64 publications
0
12
0
6
Order By: Relevance
“…This corrigendum corrects the article by Bailly et al 1 The error was published on page 58, where the article reads:…”
mentioning
confidence: 77%
“…This corrigendum corrects the article by Bailly et al 1 The error was published on page 58, where the article reads:…”
mentioning
confidence: 77%
“…Despite the similarities in presenting symptoms and tumor cell morphology between PBL and other hematologic malignancies, PBL can be distinguished based on its distinct immunophenotypic footprint. The typical immunophenotype in PBL includes positivity for CD38, CD138, MUM1/IRF4, and EBER accompanied by a high Ki-67 proliferation index [ 1 , 5 , 15 ]. As demonstrated by our patient’s case, even an atypical presentation of an uncommon pathology can be readily identified by tissue sampling followed by careful analysis of cell morphology and immunophenotype in conjunction with an experienced pathologist.…”
Section: Discussionmentioning
confidence: 99%
“…Most PBL patients present at advanced stage with frequent BM involvement [ 78 , 79 ]. PBL carries a poor prognosis with a median progression-free survival of 6 months; however, it does respond to chemotherapy and involved field radiotherapy, enabling many to achieve temporary remission [ 80 , 81 ]. CHOP remains a commonly used chemotherapy regimen, particularly in resource-constrained settings [ 81 ].…”
Section: Malignanciesmentioning
confidence: 99%